PubMed:11438314 JSONTXT

{"project":"FSU-PRGE","denotations":[{"id":"T1","span":{"begin":121,"end":140},"obj":"protein"},{"id":"T2","span":{"begin":356,"end":388},"obj":"protein"},{"id":"T3","span":{"begin":870,"end":902},"obj":"protein"},{"id":"T4","span":{"begin":1028,"end":1052},"obj":"protein"},{"id":"T5","span":{"begin":1066,"end":1069},"obj":"protein"},{"id":"T6","span":{"begin":1094,"end":1097},"obj":"protein"},{"id":"T7","span":{"begin":1175,"end":1198},"obj":"protein"},{"id":"T8","span":{"begin":1321,"end":1339},"obj":"protein"},{"id":"T9","span":{"begin":1378,"end":1394},"obj":"protein"},{"id":"T10","span":{"begin":1431,"end":1446},"obj":"protein"},{"id":"T11","span":{"begin":1611,"end":1621},"obj":"protein"},{"id":"T12","span":{"begin":1626,"end":1631},"obj":"protein"},{"id":"T13","span":{"begin":1655,"end":1666},"obj":"protein"},{"id":"T14","span":{"begin":1714,"end":1730},"obj":"protein"},{"id":"T15","span":{"begin":1735,"end":1744},"obj":"protein"}],"text":"Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism.\nOBJECTIVE: To determine the effects of lower doses of conjugated equine estrogens (CEE) alone or CEE and medroxyprogesterone acetate (MPA) on lipoproteins, carbohydrate metabolism, and coagulation/fibrinolytic factors.\nDESIGN: Randomized, double-blind, placebo-controlled study.\nSETTING: Multicenter substudy of the Women's HOPE trial.\nPATIENT(S): Seven hundred and forty-nine healthy, postmenopausal women.\nINTERVENTION(S): Women were randomized to receive the following doses in milligrams per day: 0.625 CEE; 0.625 CEE/2.5 MPA; 0.45 CEE; 0.45 CEE/2.5 MPA; 0.45 CEE/1.5 MPA; 0.3 CEE; 0.3 CEE/1.5 MPA; or placebo.\nMAIN OUTCOME MEASURE(S): Assessment of lipids, lipoproteins, glucose tolerance, and coagulation/fibrinolytic factors at baseline, cycle 6, and year 1.\nRESULT(S): One year of treatment with any of the CEE or CEE/MPA regimens studied increased high-density lipoprotein cholesterol (HDL-C); the 10% increase in HDL-C for the CEE 0.45/MPA 1.5 group was similar to the CEE 0.625/MPA 2.5 group. Low-density lipoprotein cholesterol was significantly reduced in all of the active treatment groups except the CEE 0.3/MPA 1.5 group at cycle 13. Apolipoprotein A-I and triglyceride levels increased and apolipoprotein B levels decreased in all groups. The lipoprotein (a) level was reduced in the CEE 0.45/MPA 2.5, CEE 0.45/MPA 1.5, and CEE 0.625/MPA 2.5 groups. Minimal changes were observed in carbohydrate metabolism for all groups. Fibrinogen and PAI-1 activity decreased and plasminogen activity increased in all groups. Decreases in antithrombin III and protein S activities were significant for all active treatment groups except the CEE 0.3/MPA 1.5 group.\nCONCLUSION(S): Lower doses of CEE and CEE/MPA induce favorable changes in lipids, lipoproteins, and hemostatic factors with minimal changes in carbohydrate metabolism."}